Abstract
Many soft tissue sarcoma subtypes have consistent chromosomal translocations with novel fusion genes, which result in disordered cellular function. The microscopic appearances, immunophenotype and behaviour of such tumours relate to the genetic events to a variable extent. This paper reviews the molecular pathology and related morphological and clinical features of sarcomas with non-EWS translocations. These include synovial sarcoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, dermatofibrosarcoma protuberans, low-grade fibromyxoid sarcoma, infantile fibrosarcoma and inflammatory myofibroblastic tumour.
Similar content being viewed by others
References
Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7:233–245
Fisher C (1998) Synovial sarcoma. Ann Diagn Pathol 2:401–421
McKinney CD, Mills SE, Fechner RE (1992) Intraarticular synovial sarcoma. Am J Surg Pathol 16:1017–1020
Fetsch JF, Meis JM (1992) Intra-articular synovial sarcoma. Mod Pathol 5:6A
Ishida T, Iijima T, Moriyama S et al (1996) Intra-articular calcifying synovial sarcoma mimicking synovial chondromatosis. Skeletal Radiol 25:766–769
van de Rijn M, Barr FG, Xiong QB et al (1997) Radiation-associated synovial sarcoma. Hum Pathol 28:1325–1328
Egger JF, Coindre JM, Benhattar J et al (2002) Radiation-associated synovial sarcoma: clinicopathologic and molecular analysis of two cases. Mod Pathol 15:998–1004
Deraedt K, Debiec-Rychter M, Sciot R (2006) Radiation-associated synovial sarcoma of the lung following radiotherapy for pulmonary metastasis of Wilms’ tumour. Histopathology 48:473–475
Crew AJ, Clark J, Fisher C et al (1995) Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. Embo J 14:2333–2340
Agus V, Tamborini E, Mezzelani A et al (2001) Re: A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 93:1347–1349
Otsuka S, Nishijo K, Nakayama T et al (2006) A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. Cancer Genet Cytogenet 167:82–88
Krskova L, Sumerauer D, Stejskalova E et al (2007) A novel variant of SYT-SSX1 fusion gene in a case of spindle cell synovial sarcoma. Diagn Mol Pathol 16:179–183
Amary MF, Diss TC, Flanagan AM (2007) Molecular characterization of a novel variant of a SYT-SSX1 fusion transcript in synovial sarcoma. Histopathology 51:559–561
Storlazzi CT, Mertens F, Mandahl N et al (2003) A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer 37:195–200
Brett D, Whitehouse S, Antonson P et al (1997) The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 6:1559–1564
Thaete C, Brett D, Monaghan P et al (1999) Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 8:585–591
Hashimoto N, Araki N, Yoshikawa H et al (2000) SYT-SSX fusion proteins in synovial sarcomas: detection and characterization with new antibodies. Cancer Lett 149:31–36
Saito T, Oda Y, Sakamoto A et al (2000) Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 192:342–350
Nielsen TO, West RB, Linn SC et al (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301–1307
Allander SV, Illei PB, Chen Y et al (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161:1587–1595
Fernebro J, Francis P, Eden P et al (2006) Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 118:1165–1172
Folpe AL, Schmidt RA, Chapman D et al (1998) Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 22:673–682
van de Rijn M, Barr FG, Xiong QB et al (1999) Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol 23:106–112
Pilotti S, Mezzelani A, Azzarelli A et al (1998) bcl-2 expression in synovial sarcoma. J Pathol 184:337–339
Machen SK, Fisher C, Gautam RS et al (1998) Utility of cytokeratin subsets for distinguishing poorly differentiated synovial sarcoma from peripheral primitive neuroectodermal tumour. Histopathology 33:501–507
Pelmus M, Guillou L, Hostein I et al (2002) Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol 26:1434–1440
Fisher C, Montgomery E, Healy V (2003) Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis. Histopathology 42:588–593
Olsen SH, Thomas DG, Lucas DR (2006) Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 19:659–668
Miettinen M, Limon J, Niezabitowski A et al (2001) Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 25:610–617
Ng TL, Gown AM, Barry TS et al (2005) Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 18:68–74
Terry J, Saito T, Subramanian S et al (2007) TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31:240–246
He R, Patel RM, Alkan S et al (2007) Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. Mod Pathol 20:522–528
Winnepenninckx V, De Vos R, Debiec-Rychter M et al (2001) Calcifying/ossifying synovial sarcoma shows t(X;18) with SSX2 involvement and mitochondrial calcifications. Histopathology 38:141–145
Mancuso T, Mezzelani A, Riva C et al (2000) Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 80:805–813
Antonescu CR, Kawai A, Leung DH et al (2000) Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 9:1–8
van de Rijn M, Barr FG, Collins MH et al (1999) Absence of SYT-SSX fusion products in soft tissue tumors other than synovial sarcoma. Am J Clin Pathol 112:43–49
Tamborini E, Agus V, Perrone F et al (2002) Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 34 archival cases. Lab Invest 82:609–618
Ladanyi M, Antonescu CR, Leung DH et al (2002) Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62:135–140
Ladanyi M (2005) Correlates of SYT-SSX fusion type in synovial sarcoma: getting more complex but also more interesting? J Clin Oncol 23:3638–3639 Author reply 3639–3640
Spillane AJ, A’Hern R, Judson IR et al (2000) Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 18:3794–3803
Lewis JJ, Antonescu CR, Leung DH et al (2000) Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 18:2087–2094
Trassard M, Le Doussal V, Hacene K et al (2001) Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 19:525–534
Mullen JR, Zagars GK (1994) Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol 33:23–30
Skytting BT, Bauer HC, Perfekt R et al (1999) Ki-67 is strongly prognostic in synovial sarcoma: analysis based on 86 patients from the Scandinavian Sarcoma group register [in process citation]. Br J Cancer 80:1809–1814
Bergh P, Meis-Kindblom JM, Gherlinzoni F et al (1999) Synovial sarcoma: identification of low and high risk groups. Cancer 85:2596–2607
Nilsson G, Skytting B, Xie Y et al (1999) The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 59:3180–3184
Kawai A, Woodruff J, Healey JH et al (1998) SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338:153–160
Guillou L, Benhattar J, Bonichon F et al (2004) Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 22:4040–4050
Takenaka S, Ueda T, Naka N et al (2008) Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep 19:467–476
Thomas DG, Giordano TJ, Sanders D et al (2005) Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103:830–838
Blay JY, Ray-Coquard I, Alberti L et al (2004) Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas. Cancer Treat Res 120:151–167
Tschoep K, Kohlmann A, Schlemmer M et al (2007) Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63:111–124
GE NWA, Webber BL et al (1995) Classification of Rhabdomyosarcoma and related sarcomas. Pathologic aspects and proposal for a new classification. An intragroup rhabdomyosarcoma study. Cancer 76:1073–1085
Weiss SW, Goldblum JR (2008) Soft Tissue Tumors. Mosby Elsevier, Philadelphia, pp 595–632
Downing JR, Khandekar A, Shurtleff SA et al (1995) Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing’s sarcoma. Am J Pathol 146:626–634
de Alava E, Ladanyi M, Rosai J et al (1995) Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. A specific diagnostic assay. Am J Pathol 147:1584–1591
Barr FG (2001) Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20:5736–5746
Barr FG, Qualman SJ, Macris MH et al (2002) Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 62:4704–4710
Sorensen PH, Lynch JC, Qualman SJ et al (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol 20:2672–2679
Wachtel M, Dettling M, Koscielniak E et al (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64:5539–5545
Anderson J, Ramsay A, Gould S et al (2001) PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 159:1089–1096
Keller C, Arenkiel BR, Coffin CM et al (2004) Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18:2614–2626
Begin LR, Schurch W, Lacoste J et al (1994) Glycogen-rich clear cell rhabdomyosarcoma of the mediastinum. Potential diagnostic pitfall. Am J Surg Pathol 18:302–308
Boman F, Champigneulle J, Schmitt C et al (1996) Clear cell rhabdomyosarcoma. Pediatr Pathol Lab Med 16:951–959
Chan JK, Ng HK, Wan KY et al (1989) Clear cell rhabdomyosarcoma of the nasal cavity and paranasal sinuses. Histopathology 14:391–399
Tsokos M, Webber BL, Parham DM et al (1992) Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med 116:847–855 [see comments]
Parham DM, Shapiro DN, Downing JR et al (1994) Solid alveolar rhabdomyosarcomas with the t(2;13). Report of two cases with diagnostic implications. Am J Surg Pathol 18:474–478
Parham DM, Qualman SJ, Teot L et al (2007) Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. Am J Surg Pathol 31:895–901
Kohashi K, Oda Y, Yamamoto H et al (2008) Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol 134:1097–1103
Kelly KM, Womer RB, Sorensen PH et al (1997) Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 15:1831–1836
Kazanowska B, Reich A, Stegmaier S et al (2007) Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Fetal Pediatr Pathol 26:17–31
Lae M, Ahn EH, Mercado GE et al (2007) Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 212:143–151
De Pitta C, Tombolan L, Albiero G et al (2006) Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 118:2772–2781
Davicioni E, Finckenstein FG, Shahbazian V et al (2006) Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66:6936–6946
Folpe AL, Deyrup AT (2006) Alveolar soft-part sarcoma: a review and update. J Clin Pathol 59:1127–1132
Lieberman PH, Brennan MF, Kimmel M et al (1989) Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer 63:1–13
Amin MB, Patel RM, Oliveira P et al (2006) Alveolar soft-part sarcoma of the urinary bladder with urethral recurrence: a unique case with emphasis on differential diagnoses and diagnostic utility of an immunohistochemical panel including TFE3. Am J Surg Pathol 30:1322–1325
Nielsen GP, Oliva E, Young RH et al (1995) Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. Int J Gynecol Pathol 14:283–292
Luo J, Melnick S, Rossi A et al (2008) Primary cardiac alveolar soft part sarcoma. A report of the first observed case with molecular diagnostics corroboration. Pediatr Dev Pathol 11:142–147
Fanburg-Smith JC, Miettinen M, Folpe AL et al (2004) Lingual alveolar soft part sarcoma; 14 cases: novel clinical and morphological observations. Histopathology 45:526–537
Font RL, Jurco S 3rd, Zimmerman LE (1982) Alveolar soft-part sarcoma of the orbit: a clinicopathologic analysis of seventeen cases and a review of the literature. Hum Pathol 13:569–579
Joyama S, Ueda T, Shimizu K et al (1999) Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: a case report and review of the literature. Cancer 86:1246–1250
Cullinane C, Thorner PS, Greenberg ML et al (1992) Molecular genetic, cytogenetic, and immunohistochemical characterization of alveolar soft-part sarcoma. Implications for cell of origin. Cancer 70:2444–2450
Ladanyi M, Lui MY, Antonescu CR et al (2001) The der(17) t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20:48–57
Argani P, Lal P, Hutchinson B et al (2003) Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 27:750–761
Argani P, Antonescu CR, Illei PB et al (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 159:179–192
Bruder E, Passera O, Harms D et al (2004) Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 28:1117–1132
Folpe AL, Mentzel T, Lehr HA et al (2005) Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 29:1558–1575
LP SFH, Foote FW, Stewart FW (1964) Ultrastructure of alveolar soft part sarcoma. Cancer 17:821–830
Ordonez NG, Ro JY, Mackay B (1989) Alveolar soft part sarcoma. An ultrastructural and immunocytochemical investigation of its histogenesis. Cancer 63:1721–1736
Ladanyi M, Antonescu CR, Drobnjak M et al (2002) The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol 160:1215–1221
Portera CA Jr, Ho V, Patel SR et al (2001) Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91:585–591
Casanova M, Ferrari A, Bisogno G et al (2000) Alveolar soft part sarcoma in children and adolescents: A report from the Soft-Tissue Sarcoma Italian Cooperative Group. Ann Oncol 11:1445–1449
Tsuda M, Davis IJ, Argani P et al (2007) TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67:919–929
Criscione VD, Weinstock MA (2007) Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 56:968–973
Maire G, Fraitag S, Galmiche L et al (2007) A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 143:203–210
Shmookler BM, Enzinger FM, Weiss SW (1989) Giant cell fibroblastoma. A juvenile form of dermatofibrosarcoma protuberans. Cancer 64:2154–2161
Alguacil-Garcia A (1991) Giant cell fibroblastoma recurring as dermatofibrosarcoma protuberans. Am J Surg Pathol 15:798–801
Allen PW, Zwi J (1992) Giant cell fibroblastoma transforming into dermatofibrosarcoma protuberans. Am J Surg Pathol 16:1127–1129
Goldblum JR (1996) Giant cell fibroblastoma: a report of three cases with histologic and immunohistochemical evidence of a relationship to dermatofibrosarcoma protuberans. Arch Pathol Lab Med 120:1052–1055
Wrotnowski U, Cooper PH, Shmookler BM (1988) Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol 12:287–293
Ding J, Hashimoto H, Enjoji M (1989) Dermatofibrosarcoma protuberans with fibrosarcomatous areas. A clinicopathologic study of nine cases and a comparison with allied tumors. Cancer 64:721–729
Connelly JH, Evans HL (1992) Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol 16:921–925
Diaz-Cascajo C, Weyers W, Borrego L et al (1997) Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases. Am J Dermatopathol 19:562–567
Mentzel T, Beham A, Katenkamp D et al (1998) Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 22:576–587
Abbott JJ, Oliveira AM, Nascimento AG (2006) The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol 30:436–443
Pedeutour F, Simon MP, Minoletti F et al (1996) Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 72:171–174
Simon MP, Pedeutour F, Sirvent N et al (1997) Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 15:95–98
Wang J, Hisaoka M, Shimajiri S et al (1999) Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription-polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 8:113–119
Sirvent N, Maire G, Pedeutour F (2003) Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 37:1–19
Sandberg AA, Bridge JA (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 140:1–12
Nishio J, Iwasaki H, Ohjimi Y et al (2001) Supernumerary ring chromosomes in dermatofibrosarcoma protuberans may contain sequences from 8q11.2-qter and 17q21-qter: a combined cytogenetic and comparative genomic hybridization study. Cancer Genet Cytogenet 129:102–106
Nishio J, Iwasaki H, Ishiguro M et al (2001) Supernumerary ring chromosome in a Bednar tumor (pigmented dermatofibrosarcoma protuberans) is composed of interspersed sequences from chromosomes 17 and 22: a fluorescence in situ hybridization and comparative genomic hybridization analysis. Genes Chromosomes Cancer 30:305–309
Maire G, Martin L, Michalak-Provost S et al (2002) Fusion of COL1A1 exon 29 with PDGFB exon 2 in a der(22) t(17;22) in a pediatric giant cell fibroblastoma with a pigmented Bednar tumor component. Evidence for age-related chromosomal pattern in dermatofibrosarcoma protuberans and related tumors. Cancer Genet Cytogenet 134:156–161
Wang J, Morimitsu Y, Okamoto S et al (2000) COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans. J Mol Diagn 2:47–52
Sheng WQ, Hashimoto H, Okamoto S et al (2001) Expression of COL1A1-PDGFB fusion transcripts in superficial adult fibrosarcoma suggests a close relationship to dermatofibrosarcoma protuberans. J Pathol 194:88–94
Patel KU, Szabo SS, Hernandez VS et al (2008) Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 39:184–193
Terrier-Lacombe MJ, Guillou L, Maire G et al (2003) Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data–a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 27:27–39
Sonobe H, Furihata M, Iwata J et al (1999) Dermatofibrosarcoma protuberans harboring t(9;22)(q32;q12.2). Cancer Genet Cytogenet 110:14–18
Linn SC, West RB, Pollack JR et al (2003) Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163:2383–2395
Nielsen TO (2006) Microarray Analysis of Sarcomas. Adv Anat Pathol 13:166–173
West RB, Harvell J, Linn SC et al (2004) Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 28:1063–1069
Lisovsky M, Hoang MP, Dresser KA et al (2008) Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Mod Pathol 21:31–38
Shimizu A, O’Brien KP, Sjoblom T et al (1999) The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 59:3719–3723
Greco A, Fusetti L, Villa R et al (1998) Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 17:1313–1319
Sjoblom T, Shimizu A, O’Brien KP et al (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61:5778–5783
Rubin BP, Schuetze SM, Eary JF et al (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586–3591
Maki RG, Awan RA, Dixon RH et al (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100:623–626
Kasper B, Lossignol D, Gil T et al (2006) Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs 17:1223–1225
McArthur GA (2006) Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol 18:341–346
Ostman A, Heldin CH (2007) PDGF Receptors as Targets in Tumor Treatment. Adv Cancer Res 97:247–274
McArthur GA, Demetri GD, van Oosterom A et al (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866–873
McArthur GA (2007) Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw 5:557–562
Evans HL (1987) Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol 88:615–619
Lane KL, Shannon RJ, Weiss SW (1997) Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma. Am J Surg Pathol 21:1481–1488
Evans HL (1993) Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol 17:595–600
Folpe AL, Lane KL, Paull G et al (2000) Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol 24:1353–1360
Kim L, Yoon YH, Choi SJ et al (2007) Hyalinizing spindle cell tumor with giant rosettes arising in the lung: report of a case with FUS-CREB3L2 fusion transcripts. Pathol Int 57:153–157
Saito R, Kumabe T, Watanabe M et al (2008) Low-grade fibromyxoid sarcoma of intracranial origin. J Neurosurg 108:798–802
Jakowski JD, Wakely PE Jr (2008) Primary intrathoracic low-grade fibromyxoid sarcoma. Hum Pathol 39:623–628
Winfield HL, De Las Casas LE, Greenfield WW et al (2007) Low-grade fibromyxoid sarcoma presenting clinically as a primary ovarian neoplasm: a case report. Int J Gynecol Pathol 26:173–176
Park IJ, Kim HC, Yu CS et al (2007) Low-grade fibromyxoid sarcoma of the colon. Dig Liver Dis 39:274–277
Billings SD, Giblen G, Fanburg-Smith JC (2005) Superficial low-grade fibromyxoid sarcoma (Evans tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric population. Am J Surg Pathol 29:204–210
Bejarano PA, Padhya TA, Smith R et al (2000) Hyalinizing spindle cell tumor with giant rosettes–a soft tissue tumor with mesenchymal and neuroendocrine features. An immunohistochemical, ultrastructural, and cytogenetic analysis. Arch Pathol Lab Med 124:1179–1184
Mezzelani A, Sozzi G, Nessling M et al (2000) Low grade fibromyxoid sarcoma. a further low-grade soft tissue malignancy characterized by a ring chromosome. Cancer Genet Cytogenet 122:144–148
Reid R, de Silva MV, Paterson L et al (2003) Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes share a common t(7;16)(q34;p11) translocation. Am J Surg Pathol 27:1229–1236
Panagopoulos I, Storlazzi CT, Fletcher CD et al (2004) The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer 40:218–228
Mertens F, Fletcher CD, Antonescu CR et al (2005) Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest 85:408–415
Matsuyama A, Hisaoka M, Shimajiri S et al (2006) Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. Am J Surg Pathol 30:1077–1084
Panagopoulos I, Moller E, Dahlen A et al (2007) Characterization of the native CREB3L2 transcription factor and the FUS/CREB3L2 chimera. Genes Chromosomes Cancer 46:181–191
Guillou L, Benhattar J, Gengler C et al (2007) Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol 31:1387–1402
Matsuyama A, Hisaoka M, Shimajiri S et al (2008) DNA-based Polymerase chain reaction for detecting FUS-CREB3L2 in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. Diagn Mol Pathol 17:237–240
Schofield DE, Fletcher JA, Grier HE et al (1994) Fibrosarcoma in infants and children. Application of new techniques. Am J Surg Pathol 18:14–24
Gorman PA, Malone M, Pritchard J et al (1990) Deletion of part of the short arm of chromosome 17 in a congenital fibrosarcoma. Cancer Genet Cytogenet 48:193–198
Strehl S, Ladenstein R, Wrba F et al (1993) Translocation (12;13) in a case of infantile fibrosarcoma. Cancer Genet Cytogenet 71:94–96
Boulos BM, Dajuvone C, Azarnoff DL (1976) A new method for increasing the chemotherapeutic drug concentration in the tumor tissue. Panminerva Med 18:95–98
Knezevich SR, McFadden DE, Tao W et al (1998) A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18:184–187
Sheng WQ, Hisaoka M, Okamoto S et al (2001) Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol 115:348–355
Kaplan DR, Miller FD (1997) Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol 9:213–221
Lannon CL, Martin MJ, Tognon CE et al (2004) A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation. J Biol Chem 279:6225–6234
Wai DH, Knezevich SR, Lucas T et al (2000) The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene 19:906–915
Tognon C, Garnett M, Kenward E et al (2001) The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res 61:8909–8916
Martin MJ, Melnyk N, Pollard M et al (2006) The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 26:1754–1769
Jin W, Yun C, Hobbie A et al (2007) Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res 67:3192–3200
Jin W, Kim BC, Tognon C et al (2005) The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor. Proc Natl Acad Sci U S A 102:16239–16244
Knezevich SR, Garnett MJ, Pysher TJ et al (1998) ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 58:5046–5048
Rubin BP, Chen CJ, Morgan TW et al (1998) Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153:1451–1458
Tognon C, Knezevich SR, Huntsman D et al (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2:367–376
Eguchi M, Eguchi-Ishimae M, Tojo A et al (1999) Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93:1355–1363
Fletcher C, Unni K, Mertens F (eds) (2002) World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon.
Loh ML, Ahn P, Perez-Atayde AR et al (2002) Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children’s Hospital, Boston. J Pediatr Hematol Oncol 24:722–726
Chung EB, Enzinger FM (1976) Infantile fibrosarcoma. Cancer 38:729–739
Soule EH, Pritchard DJ (1977) Fibrosarcoma in infants and children: a review of 110 cases. Cancer 40:1711–1721
Coffin CM, Jaszcz W, O’Shea PA et al (1994) So-called congenital-infantile fibrosarcoma: does it exist and what is it? Pediatr Pathol 14:133–150
Cecchetto G, Carli M, Alaggio R et al (2001) Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group studies (1979–1995). J Surg Oncol 78:225–231
Surico G, Muggeo P, Daniele RM et al (2003) Chemotherapy alone for the treatment of congenital fibrosarcoma: is surgery always needed? Med Pediatr Oncol 40:268–270
Blocker S, Koenig J, Ternberg J (1987) Congenital fibrosarcoma. J Pediatr Surg 22:665–670
Coden DJ, Hornblass A (1990) Orbital hemangiopericytoma. JAMA 264:1861
Coffin CM, Humphrey PA, Dehner LP (1998) Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol 15:85–101
Montgomery EA, Shuster DD, Burkart AL et al (2006) Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol 30:1502–1512
Hirsch MS, Dal Cin P, Fletcher CD (2006) ALK expression in pseudosarcomatous myofibroblastic proliferations of the genitourinary tract. Histopathology 48:569–578
Harik LR, Merino C, Coindre JM et al (2006) Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. Am J Surg Pathol 30:787–794
Sukov WR, Cheville JC, Carlson AW et al (2007) Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol 20:592–603
Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284
Lawrence B, Perez-Atayde A, Hibbard MK et al (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157:377–384
Bridge JA, Kanamori M, Ma Z et al (2001) Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 159:411–415
Debiec-Rychter M, Marynen P, Hagemeijer A et al (2003) ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 38:187–190
Debelenko LV, Arthur DC, Pack SD et al (2003) Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 83:1255–1265
Panagopoulos I, Nilsson T, Domanski HA et al (2006) Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 118:1181–1186
Chan JK, Cheuk W, Shimizu M (2001) Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol 25:761–768
Cessna MH, Zhou H, Sanger WG et al (2002) Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 15:931–938
Cook JR, Dehner LP, Collins MH et al (2001) Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 25:1364–1371
Coffin CM, Hornick JL, Fletcher CD (2007) Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31:509–520
Li XQ, Hisaoka M, Shi DR et al (2004) Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum Pathol 35:711–721
Coffin CM, Patel A, Perkins S et al (2001) ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 14:569–576
Biselli R, Boldrini R, Ferlini C et al (1999) Myofibroblastic tumours: neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis. Pathol Res Pract 195:619–632
Acknowledgement
The author thanks Marc Ladanyi for comments on the manuscript.
Conflict of interest statement
I declare that I have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fisher, C. Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. Virchows Arch 456, 153–166 (2010). https://doi.org/10.1007/s00428-009-0776-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-009-0776-0